Kelowna, BC – June 12, 2025 – TheNewswire – Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70) (“Doseology” or the “Company”), an innovator in precision-formulated performance solutions, is pleased to announce that it has closed its previously announced non-brokered private placement of 3,336,106 units of the Company (“Units”) at a price of $0.225 per Unit for aggregate gross proceeds of $750,624 (the “Private Placement’).

Each Unit consists of one common share (a “Common Share”) and one Common Share purchase warrant (a “Warrant”), with each Warrant exercisable to purchase one Common Share at a price of $0.50 for 24 months from the date of issuance (the “Expiry Date”), provided that in the event that the closing price of the Company’s Common Shares on the Canadian Securities Exchange (the “CSE”) (or such other exchange on which the Company’s Common Shares may become traded) is $0.75 or greater per Common Share during any ten (10) non-consecutive trading day period at any time subsequent to four months and one day after the closing date, the Warrants will expire at 4:00 p.m. (Vancouver time) on the 30th day after the date on which the Company provides notice of such accelerated expiry to the holders of the Warrants.

All securities issued pursuant to the Private Placement will be subject to a mandatory 4 month hold period, and, in addition, the securities will be restricted from trading as to (i) 33% on the date that is 4 months from closing of the Private Placement, (ii) 33% on the date that is 8 months from closing of the Private Placement, and (iii) 34% on the date that is 12 months from closing of the Private Placement.

Doseology will deploy net proceeds from the Private Placement as working capital to support the strategic rollout of its oral stimulant pouch line. Funds will be directed toward regulatory submissions, infrastructure development, commercial readiness, sales expansion, and brand growth—establishing a strong foundation for scale across Canada and the U.S. These efforts align with Doseology’s mission to deliver clean-label, science-backed, smoke-free stimulant alternatives for today’s health-conscious consumer.

    

About Doseology Sciences Inc. (CSE: MOOD | PINK: DOSEF | FSE: VU70)

Doseology is a biotech innovation company, engineering precision‑formulated oral stimulants that optimize energy, focus, and cognitive performance. Through rigorous scientific research and advanced delivery technologies, we're pioneering next‑gen performance solutions designed to empower peak performance.

On behalf of the Board of Directors,
Chris Jackson
CEO
Doseology Sciences Inc.

For more information, please contact the Company at:
Email: hello@doseology.com
Website: www.doseology.com
Phone: 604.908.3095

 

Forward Looking Statements

This press release contains statements that constitute “forward‐looking information” within the meaning of applicable securities laws. Forward‐looking information is often identified by the words “may,” “would,” “could,” “should,” “will,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “expect” or similar expressions. Readers are cautioned that forward‐looking information is not based on historical facts but instead reflects the Company’s management’s expectations, estimates or projections concerning the business of the Company’s future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although the Company believes that the expectations reflected in such forward‐looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance, or achievements. Among the key factors that could cause actual results to differ materially from those projected in the forward‐looking information are the following: changes in general economic, business and political conditions, including changes in the financial markets; decreases in the prevailing prices for products in the markets that the Company operates in; adverse changes in applicable laws or adverse changes in the application or enforcement of current laws; regulations and enforcement priorities of governmental authorities; compliance with government regulation and related costs; and other risks described in the Company’s prospectus. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward‐looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated, or expected. Although the Company has attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. The Company does not intend, and does not assume any obligation, to update this forward‐looking information  except as otherwise required by applicable law. For more information, investors should review the Company’s filings which are available on SEDAR+.

No securities regulatory authority has either approved or disapproved of the contents of this press release. The Company’s securities have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States, or to or for the account or benefit of any person in the United States, absent registration, or an applicable exemption from the registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The CSE does not accept responsibility for the adequacy or accuracy of this release.